NightHawk Biosciences' decision to become a pure-play CDMO and divest non-core assets is a significant strategic shift that could be viewed positively by the market. The focus on large molecule biomanufacturing, a growing and lucrative sector, may lead to increased investor interest and potential stock price appreciation in the short term. The divestiture of Elusys assets could also streamline operations and improve financial metrics, which is typically well-received by investors.